trending Market Intelligence /marketintelligence/en/news-insights/trending/yFHgtUhfNdRErAo_tebUfg2 content esgSubNav
In This List

Vericel's knee repair implant gets US FDA approval

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Vericel's knee repair implant gets US FDA approval

The U.S. FDA granted approval to Vericel Corp.'s Maci for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients.

Maci is composed of a patient's own cells that are expanded and placed onto a bio-resorbable porcine-derived collagen membrane that is implanted over the area where the defective or damaged tissue was removed.

The safety and efficacy of Maci were shown in a clinical trial designed to demonstrate reduced pain and improved function in comparison to microfracture, an alternative surgical procedure for cartilage repair.